SAM
BIO icon

Shell Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Shell Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$19K Sell
66
-168
-72% -$45.7K ﹤0.01% 1040
2025
Q2 		$56K Sell
234
-26
-10% -$6.15K ﹤0.01% 1125
2025
Q1 		$63K Sell
260
-11
-4% -$3.31K ﹤0.01% 1103
2024
Q4 		$89K Hold
271
– – ﹤0.01% 1067
2024
Q3 		$91K Buy
+271
New +$86.1K ﹤0.01% 1064
2024
Q1 		$78K Sell
287
-31
-10% -$10.2K ﹤0.01% 1080
2023
Q4 		$103K Sell
318
-94
-23% -$29.5K ﹤0.01% 1049
2023
Q3 		$148K Sell
412
-6
-1% -$2.31K 0.01% 993
2023
Q2 		$158K Sell
418
-311
-43% -$127K 0.01% 999
2023
Q1 		$349K Sell
729
-1
-0.1% -$468 0.01% 721
2022
Q4 		$307K Sell
730
-157
-18% -$63.4K 0.01% 769
2022
Q3 		$370K Sell
887
-233
-21% -$116K 0.01% 724
2022
Q2 		$554K Buy
1,120
+1
+0.1% +$521 0.02% 661
2022
Q1 		$630K Sell
1,119
-168
-13% -$101K 0.01% 696
2021
Q4 		$972K Sell
1,287
-1
-0.1% -$748 0.02% 569
2021
Q3 		$961K Sell
1,288
-660
-34% -$494K 0.02% 534
2021
Q2 		$1.25M Buy
1,948
+743
+62% +$452K 0.02% 477
2021
Q1 		$688K Sell
1,205
-882
-42% -$522K 0.01% 703
2020
Q4 		$1.22M Sell
2,087
-556
-21% -$317K 0.03% 465
2020
Q3 		$1.36M Hold
2,643
– – 0.03% 399
2020
Q2 		$1.19M Sell
2,643
-1,287
-33% -$568K 0.03% 402
2020
Q1 		$1.38M Sell
3,930
-36
-0.9% -$13.2K 0.04% 362
2019
Q4 		$1.47M Buy
3,966
+70
+2% +$24.7K 0.03% 428
2019
Q3 		$1.3M Sell
3,896
-21
-0.5% -$6.85K 0.03% 447
2019
Q2 		$1.22M Sell
3,917
-57
-1% -$17.1K 0.03% 480
2019
Q1 		$1.22M Buy
3,974
+734
+23% +$198K 0.03% 486
2018
Q4 		$752K Sell
3,240
-880
-21% -$236K 0.02% 644
2018
Q3 		$1.29M Buy
4,120
+2,760
+203% +$857K 0.03% 531
2018
Q2 		$392K Buy
+1,360
New +$376K 0.01% 985

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Shell Asset Management's BIO Position: Q3 2025 in Review

Shell Asset Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 72% in Q3 2025, selling an estimated $45.7K and leaving 66 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Shell Asset Management first reported a position in BIO in Q2 2018 and has held it in 29 quarters since. The position peaked at $1.47M in Q4 2019. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Shell Asset Management held 66 shares of Bio-Rad Laboratories Class A worth $19K as of Q3 2025.
  • Shell Asset Management sold 168 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $45.7K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1040 holding.
  • Shell Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2018 and has held it in 29 quarters since.
  • Shell Asset Management's Bio-Rad Laboratories Class A position peaked at $1.47M in Q4 2019.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.